表纸
市场调查报告书

思觉失调症伴随的认知障碍 (CIAS):开发中产品分析

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2019

出版商 Global Markets Direct 商品编码 255980
出版日期 内容资讯 英文 84 Pages
订单完成后即时交付
价格
Back to Top
思觉失调症伴随的认知障碍 (CIAS):开发中产品分析 Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2019
出版日期: 2019年02月01日内容资讯: 英文 84 Pages
简介

本报告提供世界各国的思觉失调症伴随的认识功能障碍 (以下CIAS) 治疗用的开发中产品的开发情形相关分析,开发中产品的最新趋势,及临床实验的各阶段的产品一览,主要企业的简介,主要药物概要,最新的产业趋势等的调查结果,为您概述为以下内容。

简介

  • 调查范围

思觉失调症伴随的认知障碍 (CIAS) - 概要

思觉失调症伴随的认知障碍 (CIAS) - 治疗药的开发

  • 开发平台概要
  • 各企业的开发平台趋势
  • 各大学、研究机关的开发平台趋势
  • 企业开发中的产品
  • 在大学、研究机关开发中的产品

思觉失调症伴随的认知障碍 (CIAS) - 治疗药的评估

  • 各标的
  • 各作用机制
  • 各给药途径
  • 各分子类型

开发思觉失调症伴随的认知障碍 (CIAS)的治疗药的企业

  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Biogen Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cadent Therapeutics Inc
  • Coronis NeuroSciences Ltd
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • Iproteos SL
  • Pfizer Inc
  • SK Biopharmaceuticals Co Ltd
  • Sosei Heptares
  • Spherium Biomed SL
  • 武田药品工业
  • Vanda Pharmaceuticals Inc

思觉失调症伴随的认知障碍 (CIAS)

思觉失调症伴随的认知障碍 (CIAS) - 暂停中的计划

思觉失调症伴随的认知障碍 (CIAS) - 开发中止的产品

思觉失调症伴随的认知障碍 (CIAS) - 产品开发里程碑

  • 主要消息和新闻稿

附录

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: GMDHC11053IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2019, provides an overview of the Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline landscape.

Cognitive functioning is moderately to severely impair in patients with schizophrenia. Symptoms include poor executive functioning, inability to sustain attention and problems with working memory. Predisposing factors include family history, age and autoimmune diseases. Treatment includes antipsychotic medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 5, 11 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc
    • AstraZeneca Plc
    • Biogen Inc
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Co
    • Cadent Therapeutics Inc
    • Coronis NeuroSciences Ltd
    • Eli Lilly and Co
    • F. Hoffmann-La Roche Ltd
    • Iproteos SL
    • Pfizer Inc
    • SK Biopharmaceuticals Co Ltd
    • Sosei Heptares
    • Spherium Biomed SL
    • Takeda Pharmaceutical Co Ltd
    • Vanda Pharmaceuticals Inc
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Drug Profiles
    • ASP-4345 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-5736 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUT-9 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AVL-3288 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • basmisanil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-425809 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIIB-104 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMS-955829 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAD-8688 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • erteberel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HTL-9936 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IPR-19 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LSN-2814617 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-03463275 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKL-20540 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Dopamine D1 Receptor for Cognitive Impairment Associated with Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Modulate CHRM for Central Nervous System and Respiratory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-14040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVND-4010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SUVNG-3031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-041 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-831 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VQW-765 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VU-0467154 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Product Development Milestones
    • Featured News & Press Releases
      • Feb 01, 2015: ASCIL Biopharm cooperates in a Project awarded with a "RETOS-Colaboracion" grant
      • Jan 27, 2015: Spark, a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia
      • Apr 17, 2013: SK Biopharma Announces FDA's Authorization Of IND For SKL15508 For Treatment Of Cognitive Impairment Associated With Schizophrenia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Astellas Pharma Inc, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by AstraZeneca Plc, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Biogen Inc, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Boehringer Ingelheim GmbH, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Bristol-Myers Squibb Co, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Cadent Therapeutics Inc, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Coronis NeuroSciences Ltd, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Eli Lilly and Co, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Iproteos SL, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Pfizer Inc, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Sosei Heptares, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Spherium Biomed SL, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline by Vanda Pharmaceuticals Inc, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Cognitive Impairment Associated With Schizophrenia (CIAS) - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Cognitive Impairment Associated With Schizophrenia (CIAS), H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top